Prognostic Study of HPV Virus Integration in Women With HSIL

Launched by FUJIAN MATERNITY AND CHILD HEALTH HOSPITAL · Feb 16, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at the connection between the HPV virus and a condition called high-grade squamous intraepithelial lesions (HSIL) in women. HSIL is a serious change in the cells of the cervix that can sometimes lead to cervical cancer. The researchers want to understand how the way HPV is integrated into the body affects the health outcomes of women with HSIL. They are also interested in how different types of HPV may relate to the balance of bacteria in the vagina, which can influence overall health.

If you are a woman with a confirmed diagnosis of HSIL and have not had any surgical treatment for this condition, you may be eligible to participate in this trial. Unfortunately, women who are pregnant or breastfeeding, or who have had previous surgeries or treatments for similar issues in the past month cannot join. Participants will need to give their consent and can expect to undergo some tests to provide information about their HPV status and overall health. This study aims to help improve understanding and treatment options for women affected by HSIL and HPV.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Pathologically confirmed HSIL(CIN2, 3) in women or cervical carcinoma in situ or early invasive cancer;
• • No surgical treatment or conization only;
• • Obtain informed consent.
• Exclusion Criteria:
• • During pregnancy or lactation;
• • Patients with a history of genital tract cancer;
• • Previous history of hysterectomy, cervical surgery or pelvic radiotherapy;
• • Received treatment related to genital tract infection, HPV or other STDs pathogen infection in the past one month;
• • Use of antibiotics or vaginal microecological improvement products in the past 1 month.